TY - JOUR
T1 - MAOI treatment response
T2 - multiaxial assessment
AU - Giller, Earl
AU - Bialos, Donald
AU - Riddle, Mark A.
AU - Waldo, Merilyne C.
N1 - Funding Information:
This work was supported in part by VA Research Funds. We thank John Strauss, M.D., Laurie Harkness, MSW, and Alan Fontana, Ph.D. for helpful discussions, Emmanuel Lerner for statistical consultation, Margo Cinquanta for data coding, and Karen Arena for manuscript preparation.
PY - 1988
Y1 - 1988
N2 - While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.
AB - While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.
KW - Monoamine oxidase inhibitor treatment
KW - Multiaxial assessment
UR - http://www.scopus.com/inward/record.url?scp=0023861065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023861065&partnerID=8YFLogxK
U2 - 10.1016/0165-0327(88)90060-2
DO - 10.1016/0165-0327(88)90060-2
M3 - Article
C2 - 2966831
AN - SCOPUS:0023861065
SN - 0165-0327
VL - 14
SP - 171
EP - 175
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
IS - 2
ER -